Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPX-100 in Metastatic Breast Cancer
NCT00123877Phase 2Terminated
- Sponsor
- Gem Pharmaceuticals
- Start
- Mar 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 13-deoxydoxorubicin in breast cancer, sponsored by Gem Pharmaceuticals. Primary endpoints: Objective Clinical Response and Decrease in Cardiac Ejection Fraction. Started Mar 2005; status: terminated.
02
Drugs
13-deoxydoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00123877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123877.